Almirall takes up option on lebrikizumab

25 June 2019
almirall_logo_plain_large

Spain’s largest drugmaker Almirall (ALM: MC) has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe from USA-based Dermira (Nasdaq: DERM).

Almirall and Dermira previously entered into an option and license agreement in February 2019 under which Almirall was granted this exclusive option in exchange for an upfront option fee of $30 million. As a result of Almirall's decision, the company will pay Dermira $50 million and Dermira will be eligible to receive additional payments upon the achievement of certain milestones, including $30 million in connection with the initiation of certain Phase III clinical studies.

Almirall’s shares edged up 1.6% to 15.74 euros by late afternoon, while Dermira was up 3.26% at $9.82 in mid-morning Nasdaq trading.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology